# LMY-920

Source: https://onco.cc/drugs/lmy-920/  
OnCo record `lmy-920` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

LMY-920 is an experimental CAR-T treatment from Luminary Therapeutics, made from a patient's own immune cells, aimed at three receptors on cancerous B cells. It is in early trials in lymphoma and myeloma.

## Summary

LMY-920 is a BAFF ligand-based CAR-T cell therapy developed by Luminary Therapeutics. Two phase 1 trials sponsored by Luminary are registered: NCT05312801 in B-cell non-Hodgkin lymphoma with Case Comprehensive Cancer Center, and NCT05546723 in relapsed or refractory multiple myeloma with Cleveland Clinic and Case Western Reserve University. No results have been published.

## Fields

- Kind: Treatment
- Status: phase-1
- Last checked: 2026-11-04
- Also known as: BAFF CAR-T; BAFF-L CAR T cells
- Tags: pipeline
- Code: LMY-920
- Modality: Autologous CAR-T cell therapy (BAFF ligand-based CAR)
- Mechanism: T cells carry a chimeric antigen receptor built on the BAFF ligand, so each cell can bind three BAFF receptors on malignant B cells.

## Sources

- ClinicalTrials.gov: NCT05312801: https://clinicaltrials.gov/study/NCT05312801
- ClinicalTrials.gov: NCT05546723: https://clinicaltrials.gov/study/NCT05546723
- Luminary Therapeutics: pipeline: https://www.luminarytx.com/pipeline/

## Connected records

- technologies: [CAR-T cell therapy](https://onco.cc/technologies/car-t/)
- companies: [Luminary Therapeutics](https://onco.cc/companies/luminary-therapeutics/)

---
JSON: https://onco.cc/api/v1/entities/lmy-920.json